Printer Friendly

T CELL SCIENCES NAMES UNA S. RYAN, PH.D. VICE PRESIDENT RESEARCH AND CHIEF SCIENTIFIC OFFICER

 CAMBRIDGE, Mass., March 22 /PRNewswire/ -- T Cell Sciences, Inc., (NASDAQ: TCEL), today announced that Una S. Ryan, Ph.D. has joined the company as vice president research and chief scientific officer.
 Dr. Ryan joined T Cell Sciences from Monsanto Co., where she was director of health sciences since 1990. During the same period she held the position of research professor of surgery, medicine and cell biology at Washington University, School of Medicine. From 1967 to 1990, Dr. Ryan held several positions at the University of Miami, most recently as professor of medicine and chief, division of vascular cell biology. Dr. Ryan received bachelor of science degrees in chemistry, microbiology and zoology from Bristol University, Bristol, England in 1963 as well as a Ph.D. from Cambridge University, Cambridge, England in 1968.
 "We are thrilled to have attracted a scientist such as Dr. Ryan with a prolific publishing history, a number of academic and professional honors and substantial involvement in leading review and advisory committees," said Alan W. Tuck, president and chief executive officer of T Cell Sciences. "Dr. Ryan's early work in culturing endothelial cells demonstrated their biological and regulatory activity and involvement in many disease conditions. Her particular expertise in the biological events leading to inflammatory tissue damage will add greatly to one of the company's primary therapeutic programs which involves the complement pathway and its role in inflammatory medical conditions. The company's first product candidate in this program entered clinical trials in Dec. 1992."
 Dr. Ryan completes the senior management team of T Cell Sciences. She joins Patrick Kung, Ph.D. the company's scientific founder who continues in his current capacity as vice chairman of the board; Alfred Rudolph, M.D. senior vice president with responsibility for product development; and Jacqueline Arthur, vice president and chief financial officer with responsibility for commercial operations.
 Located in Cambridge, Mass., T Cell Sciences, Inc. is utilizing proprietary T cell and soluble receptor technology to develop pharmaceutical products to treat diseases of inflammation, autoimmunity and cancer. T Cell Diagnostics, an 84 percent owned subsidiary of T Cell Sciences, develops, manufactures and markets highly innovative diagnostic and research products around the world.
 -0- 3/22/93
 /CONTACT: Alan W. Tuck, president and chief executive officer, or Susan Primrose, manager, corporate development & communications, both of T Cell Sciences, Inc., 617-621-1400/
 (TCEL)


CO: T Cell Sciences, Inc. ST: Massachusetts IN: MTC SU: PER

DJ-CH -- NE013 -- 8319 03/22/93 15:10 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 22, 1993
Words:407
Previous Article:H.B. FULLER COMPANY REPORTS FIRST QUARTER SALES AND EARNINGS
Next Article:HOUGHTON MIFFLIN COMPANY REPORTS POSITIVE OUTLOOK FOR 1993


Related Articles
TCELL SCIENCES PRESENTS INITIAL DATA ON NOVEL COMPLEMENT/CELL ADHESION INHIBITOR FOR THE TREATMENT OF INFLAMMATORY CONDITIONS
T CELL SCIENCES NAMES NEW SCIENTIFIC ADVISORY BOARD MEMBERS
T CELL SCIENCES AND COLLABORATORS DEMONSTRATE ABILITY TO BLOCK HYPERACUTE XENOGRAFT ORGAN REJECTION USING SCR1
T CELL SCIENCES REPORTS TP10 PHASE I MYOCARDIAL INFARCTION DATA AT AMERICAN HEART ASSOCIATION CONFERENCE
T CELL SCIENCES AND MYCOSEARCH SIGN COLLABORATIVE AGREEMENT
T CELL SCIENCES ANNOUNCES CHANGES IN MANAGEMENT
T CELL SCIENCES ANNOUNCES BOARD RESIGNATION
T CELL SCIENCES, INC. BEGINS PHASE I/II TRIAL OF TP10 FOR REPERFUSION INJURY FOLLOWING LUNG TRANSPLANT SURGERY
T Cell Sciences, Inc. Prices Public Offering of 5.0 Million Shares
T Cell Sciences Receives Three U.S. Patent Allowances For its Lead Complement Inhibitor, TP10

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters